![](/img/cover-not-exists.png)
PSS15 THE COST-EFFECTIVENESS OF RANIBIZUMAB (LUCENTIS®) IN TREATING PATIENTS WITH PREDOMINANTLY CLASSIC, MINIMALLY CLASSIC, AND OCCULT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD)
A Turpcu, JW HayVolume:
11
Year:
2008
Language:
english
DOI:
10.1016/s1098-3015(10)70910-4
File:
PDF, 89 KB
english, 2008